undamentalytics Newsletter
Sign in

Wave Life Sciences, Inc. income statement

In fiscal 2025, Wave Life Sciences, Inc. reported revenue of $42.7m, down 60.5% on the year before, operating income of −$215m (a -504.1% margin) and net income of −$204m, or −$1.21 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue0141416204141131084371
Research and development94179134175131122116130160183205
General and administrative101627404943465151597593
Operating income−19−56−102−160−208−153−127−163−68−110−215−228
Net interest income0———————————
Income before tax−19−55−101−147−194−151−122−161−58−97−204−211
Income tax00100−1−01−1000
Net income−19−56−102−147−194−150−122−162−58−97−204−211
Diluted EPS−$1.83−$2.44−$3.85−$5.06−$5.72−$3.82−$2.36−$2.05−$0.54−$0.70−$1.21−$1.07
Diluted shares (average)11m23m27m29m34m39m52m79m106m138m169m197m
EBITDA−19−55−100−154−201−145−120−156−63−107−212−224

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: VRDN vs WVECGEN vs WVERXRX vs WVECYTK vs WVE

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Wave Life Sciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Wave Life Sciences, Inc.